Helicobacter pylori infection
Conditions
Interventions
control group:Bismuth-Containing Quadruple Therapy: 10 mg of rabeprazole, 1 g of amoxicillin, 500 mg of clarithromycin, and 200 mg of colloidal bismuth twice daily for 14 days.
experimental group:Dual Therapy: 20 mg of vonoprazan twice daily and 1 g of amoxicillin 3 times daily for 10 days.
Sponsors
The First Affiliated Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.participants aged 18–70 years; 2. absent history of receiving H.pylori eradication therapy; 3.confirmed H. pylori infection by at least 1 of the following tests: urea breath test, histology examination, and positive bacterial culture.
Exclusion criteria
Exclusion criteria: 1. Used antibiotics,bismuth,or acid inhibitor use, including H2 receptor antagonist, PPI or P-CAB within four weeks before inclusion; 2. Current pregnancy or breastfeeding; 3. Allergy to any of the study drugs; 4. History of gastrectomy; 5. Gastric malignancy; 6. Gastroduodenal ulcer with recent hemorrhage or signs of hemorrhage within 4 weeks; 7. Preexisting serious diseases or clinical conditions that might interfere with the evaluation of study treatment; 8. Hepatic or renal dysfunction; 9. Patients with prolonged QT interval, a history of ventricular arrhythmia, or hypokalemia; 10. Administration of astemizole, cisapride, pimozide, terfenadine, ergotamine/Dihydroergotamine, oral midazolam, colchicine, ticagrelor/ranolazine, statins, azanavir, or lipivirin during the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eradication rates of Helicobacter pylori; | — |
Secondary
| Measure | Time frame |
|---|---|
| adverse events;compliance; | — |
Countries
China
Contacts
Public ContactTianlian Yan
The First Affiliated Hospital, Zhejiang University School of Medicine
Outcome results
None listed